Table 1 Association of obatoclax... | American Society of Hematology

Table 1

Association of obatoclax sensitivity in infant ALL/bilineal acute leukemia with clinical covariates and molecular/cytogenetic characteristics

	N (%)	EC₅₀ [nM] range/mean/median	Wilcoxon P value
Total	54 (100)	10-834/ 136/ 75.5
Age			.5327
≤90 days	18 (33)	10-834/ 152/ 87
>90 days	36 (67)	92-365/ 145/ 86
Sex			.3561
Male	33 (61)	10-834/ 143/ 98
Female	21 (39)	22-550/ 126/ 58
WBC			NA
≥50 × 10³/μL	53 (98)	10-834/ 136/ 75
<50 × 10³/μL	1 (2)	163
MLL Status			.8368; MLL-R vs G
Rearranged	47 (87)	10-834/ 135/ 75
MLL-AF4(AFF1)	28 (52)	26-834/ 168/ 109	.03774; MLL-AF4 vs MLL-ENL/Other MLL-R/MLL-G .04409; MLL-AF4 vs MLL-ENL
MLL-ENL(MLLT1)	11 (20)	13-294/ 76/ 67
Other MLL-R*	8 (15)	10-356/ 101/ 41
Germline	7 (13)	31-488/ 145/ 78
Event**			.3274
Yes	32 (68)	13-435/ 116/ 100
No	15 (32)	10-488/ 116/ 53

	N (%)	EC₅₀ [nM] range/mean/median	Wilcoxon P value
Total	54 (100)	10-834/ 136/ 75.5
Age			.5327
≤90 days	18 (33)	10-834/ 152/ 87
>90 days	36 (67)	92-365/ 145/ 86
Sex			.3561
Male	33 (61)	10-834/ 143/ 98
Female	21 (39)	22-550/ 126/ 58
WBC			NA
≥50 × 10³/μL	53 (98)	10-834/ 136/ 75
<50 × 10³/μL	1 (2)	163
MLL Status			.8368; MLL-R vs G
Rearranged	47 (87)	10-834/ 135/ 75
MLL-AF4(AFF1)	28 (52)	26-834/ 168/ 109	.03774; MLL-AF4 vs MLL-ENL/Other MLL-R/MLL-G .04409; MLL-AF4 vs MLL-ENL
MLL-ENL(MLLT1)	11 (20)	13-294/ 76/ 67
Other MLL-R*	8 (15)	10-356/ 101/ 41
Germline	7 (13)	31-488/ 145/ 78
Event**			.3274
Yes	32 (68)	13-435/ 116/ 100
No	15 (32)	10-488/ 116/ 53

NA, not applicable

Rearrangements include 2 MLL-AF9 (MLLT3), 1 MLL-EPS15, 1 MLL-ASAH3, and 4 MLL-R, not AF4, ENL, or AF9.

47 COG P9407 treatment-eligible cases; events include induction failure, induction death, relapse, remission death, and second malignancy.